BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29995404)

  • 1. Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.
    Bian T; Chandagirikoppal Vijendra K; Wang Y; Meacham A; Hati S; Cogle CR; Sun H; Xing C
    J Med Chem; 2018 Aug; 61(15):6892-6903. PubMed ID: 29995404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy.
    Das SG; Hermanson DL; Bleeker N; Lowman X; Li Y; Kelekar A; Xing C
    ACS Chem Biol; 2013 Feb; 8(2):327-35. PubMed ID: 23102022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4H-Chromene-based anticancer agents towards multi-drug resistant HL60/MX2 human leukemia: SAR at the 4th and 6th positions.
    Puppala M; Zhao X; Casemore D; Zhou B; Aridoss G; Narayanapillai S; Xing C
    Bioorg Med Chem; 2016 Mar; 24(6):1292-7. PubMed ID: 26867486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXL146, a Novel 4
    Bian T; Tagmount A; Vulpe C; Vijendra KC; Xing C
    Mol Pharmacol; 2020 Jun; 97(6):402-408. PubMed ID: 32276963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
    Das SG; Srinivasan B; Hermanson DL; Bleeker NP; Doshi JM; Tang R; Beck WT; Xing C
    J Med Chem; 2011 Aug; 54(16):5937-48. PubMed ID: 21780800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
    Aridoss G; Zhou B; Hermanson DL; Bleeker NP; Xing C
    J Med Chem; 2012 Jun; 55(11):5566-81. PubMed ID: 22582991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML.
    Bleeker NP; Cornea RL; Thomas DD; Xing C
    Mol Pharm; 2013 Nov; 10(11):4358-66. PubMed ID: 24079514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells.
    Zhou Q; Chen Y; Zhang L; Zhong Y; Zhang Z; Wang R; Jin M; Gong M; Qiu Y; Kong D
    Oncotarget; 2017 Jun; 8(24):39064-39076. PubMed ID: 28388564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.
    Hermanson DL; Das SG; Li Y; Xing C
    Mol Pharmacol; 2013 Aug; 84(2):236-43. PubMed ID: 23696245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells.
    Zhang L; Wang Z; Khishignyam T; Chen T; Zhou C; Zhang Z; Jin M; Wang R; Qiu Y; Kong D
    Biomed Pharmacother; 2018 Jul; 103():1069-1078. PubMed ID: 29710665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Anticancer Study of Novel 4H-Chromen Derivatives.
    Lu X; Dong G; Zheng Y; Zhang C; Qiu Y; Lua T; Zhou X
    Anticancer Agents Med Chem; 2017; 17(8):1070-1083. PubMed ID: 27141877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative effect, cell cycle arrest and apoptosis generation of novel synthesized anticancer heterocyclic derivatives based 4H-benzo[h]chromene.
    Alblewi FF; Okasha RM; Hritani ZM; Mohamed HM; El-Nassag MAA; Halawa AH; Mora A; Fouda AM; Assiri MA; Al-Dies AM; Afifi TH; El-Agrody AM
    Bioorg Chem; 2019 Jun; 87():560-571. PubMed ID: 30928878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
    Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
    Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, Fluorescence Properties, and Antiproliferative Potential of Several 3-Oxo-3H-benzo[f]chromene-2-carboxylic Acid Derivatives.
    Fu XB; Wang XF; Chen JN; Wu DW; Li T; Shen XC; Qin JK
    Molecules; 2015 Oct; 20(10):18565-84. PubMed ID: 26473819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computer-Aided Search for 5-Arylideneimidazolone Anticancer Agents Able To Overcome ABCB1-Based Multidrug Resistance.
    Kaczor A; Szemerédi N; Kucwaj-Brysz K; Dąbrowska M; Starek M; Latacz G; Spengler G; Handzlik J
    ChemMedChem; 2021 Aug; 16(15):2386-2401. PubMed ID: 33929088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of bioreductive activation of antitumour anthracycline drugs in cytotoxic activity against sensitive and multidrug resistant leukaemia HL60 cells.
    Kostrzewa-Nowak D; Bieg B; Paine MJ; Wolf CR; Tarasiuk J
    Eur J Pharmacol; 2012 Jan; 674(2-3):112-25. PubMed ID: 22115891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quercetin-glutamic acid conjugate with a non-hydrolysable linker; a novel scaffold for multidrug resistance reversal agents through inhibition of P-glycoprotein.
    Kim MK; Kim Y; Choo H; Chong Y
    Bioorg Med Chem; 2017 Feb; 25(3):1219-1226. PubMed ID: 28043777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples.
    Khamenehfar A; Gandhi MK; Chen Y; Hogge DE; Li PC
    Anal Chem; 2016 Jun; 88(11):5680-8. PubMed ID: 27149245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.